Cyril B. Dousson
Montpellier, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection?
Journal: Journal of hepatology
Published: January 12, 2021
Synthesis and Antiviral Evaluation of Carbocyclic Nucleoside Analogs of Nucleoside Reverse Transcriptase Translocation Inhibitor MK-8591 (4'-Ethynyl-2-fluoro-2'-deoxyadenosine).
Journal: Journal of medicinal chemistry
Published: September 29, 2018
Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection.
Journal: Antiviral chemistry & chemotherapy
Published: February 22, 2018
The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: June 20, 2017
Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor.
Journal: Bioorganic & medicinal chemistry letters
Published: November 07, 2016
Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.
Journal: Journal of medicinal chemistry
Published: January 26, 2016
Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.
Journal: Bioorganic & medicinal chemistry letters
Published: November 16, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026